| | | | | | | | | | | | | | | | |
| |
![Collapse](/DXR.axd?r=1_87-p7f1t) | Issue Date FY: 2024 ( Subtotal = $21,548,077 ) (Continued on the next page) |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01HL151902 | Assessing the burden of dementia in transgender populations | 000 | 4 | NIH | 3/28/2024 | $166,277 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23HL165097 | From Hypertensive Pregnancy to Heart Health: Understanding and Addressing Multi-Level Barriers to Cardiovascular Health after Hypertensive Disorders of Pregnancy | 000 | 1 | NIH | 2/2/2024 | $88,747 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23HL165097 | From Hypertensive Pregnancy to Heart Health: Understanding and Addressing Multi-Level Barriers to Cardiovascular Health after Hypertensive Disorders of Pregnancy | 000 | 1 | NIH | 2/2/2024 | $84,210 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01MH109651 | Elucidating mechanistic connections between guidance signaling, microtubule regulation, and growth cone steering | 000 | 8 | NIH | 12/21/2023 | $391,832 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T32HS022242 | Training in Health Services Research for Vulnerable Populations | 002 | 12 | AHRQ | 6/26/2024 | $257,896 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DA033211 | Advancing Clinical Research Training within Addiction Residency Programs | 001 | 11 | NIH | 3/15/2024 | $373,451 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T32AI052074 | BU Clinical HIV/AIDS Research Training Program (BU-CHART | 000 | 19 | NIH | 6/3/2024 | $542,752 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DA013582 | Clinical Addiction Research and Education (CARE) Program | 000 | 23 | NIH | 6/4/2024 | $372,077 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D3349076 | Preventive Medicine Residency | 01 | 2 | HRSA | 5/30/2024 | $247,386 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D3349076 | Preventive Medicine Residency | 00 | 2 | HRSA | 3/15/2024 | $147,368 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK134616 | Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease | 004 | 3 | NIH | 5/17/2024 | $24,827 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK134616 | Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease | 003 | 3 | NIH | 3/13/2024 | $372,422 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI172843 | Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission | 000 | 3 | NIH | 7/18/2024 | $703,914 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL155451 | Targeting PGC-1a for the treatment of sickle cell disease | 000 | 3 | NIH | 5/10/2024 | $350,000 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AA030460 | Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention" | 000 | 3 | NIH | 6/28/2024 | $646,689 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | 90ZT0224 | The Moving Forward Initiative for Survivors of Torture and Their Families | 00 | 3 | ACF | 7/8/2024 | $487,341 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK133404 | Investigation of the role of VEGFA in harnessing cholangiocyte-driven liver regeneration | 000 | 3 | NIH | 5/7/2024 | $554,527 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01DA052821 | Perinatal care as a venue to reduce opioid overdoses and hepatitis C virus incidence (PreVenT OD HCV) | 000 | 3 | NIH | 7/11/2024 | $175,694 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK133940 | New Therapeutic Leads for Proteinuric Kidney Diseases | 000 | 3 | NIH | 5/9/2024 | $256,320 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H9746074 | Special Projects of National Significance - Demonstration/Implementation Sites | 00 | 3 | HRSA | 7/2/2024 | $299,993 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MH127308 | Adaptation and assessment of a common element treatment protocol designed to improve mental health in forcibly displaced populations | 000 | 3 | NIH | 3/15/2024 | $184,367 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MH128639 | Medicaid Accountable Care Organizations (ACO) and Quality of Care for Adults with Serious Mental Illness (SMI) | 000 | 3 | NIH | 2/9/2024 | $189,431 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T3210028 | NATIONAL RESEARCH SERVICE AWARD | 00 | 27 | HRSA | 7/2/2024 | $437,814 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23DA054363 | Retention and Re-Engagement in Treatment for Addiction following Serious Injection Related Infections (RETAIN) | 000 | 4 | NIH | 5/22/2024 | $189,432 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA054268 | MOUD Comparative Effectiveness Study | 000 | 4 | NIH | 5/1/2024 | $542,395 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H1224845 | Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare | 00 | 12 | HRSA | 6/28/2024 | $360,381 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DK128858 | The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) | 002 | 4 | NIH | 5/16/2024 | $4,970 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DK128858 | The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) | 001 | 4 | NIH | 5/14/2024 | $7,456 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DK128858 | The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) | 000 | 4 | NIH | 2/21/2024 | $111,830 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23NS116033 | Dynamic Risk Prediction of Life-Threatening Mass Effect After Ischemic Stroke | 001 | 4 | NIH | 5/14/2024 | $33,250 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23NS116033 | Dynamic Risk Prediction of Life-Threatening Mass Effect After Ischemic Stroke | 000 | 4 | NIH | 3/29/2024 | $184,244 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HS028814 | Implementing Telemedicine to Improve Appropriate Antibiotic Prescribing for Acute Respiratory Tract Infections | 000 | 3 | AHRQ | 5/9/2024 | $487,417 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R13DA052198 | Substance Use Modeling Consortium Workshop to Support the Public Health Response to the Overdose Crisis in North America | 001 | 4 | NIH | 7/8/2024 | $24,956 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23AI152930 | Understanding HIV's impact on RR/MDR-TB development and transmission through genomics | 000 | 4 | NIH | 6/10/2024 | $186,325 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA055488 | Persistent HIV-1 expression and microglia dysfunction | 000 | 4 | NIH | 5/17/2024 | $739,881 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23HL145126 | Improving Prehospital Pediatric Emergency Readiness with Telemedicine | 001 | 5 | NIH | 7/23/2024 | $166,321 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01DA054328 | Improving value-based healthcare delivery for opioid use disorder | 000 | 4 | NIH | 6/19/2024 | $175,889 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H79SM084960 | Boston Services for Trauma And Resources for families (Boston STAR) | 003 | 4 | SAMHSA | 6/12/2024 | $380,797 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DE029862 | Validation of Light Scattering Spectroscopy for Intra-operative Margin Guidance during Oral Cancer Resection | 000 | 5 | NIH | 7/1/2024 | $703,116 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23DK119542 | The Role of Dietary Nutrients in Chronic Kidney Disease Progression and Apolipoprotein L1 Nephropathy | 000 | 5 | NIH | 3/18/2024 | $185,132 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T3442136 | Primary Care Training and Enhancement-Community Prevention and Maternal Health | 00 | 4 | HRSA | 5/24/2024 | $589,916 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T2537593 | Addiction Medicine Fellowship | 01 | 5 | HRSA | 7/23/2024 | $24,612 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T2537593 | Addiction Medicine Fellowship | 00 | 5 | HRSA | 5/24/2024 | $786,697 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01NS128342 | Addressing an inherent bias in neuroprognostication: A collaboration between the US and Brazil to reduce the impact of Self-fulfilling Prophecy in cardiac ARrEst (SPARE) | 000 | 1 | NIH | 1/19/2024 | $782,427 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R03HL171172 | Developing an assessment toolkit and training for teleconsultation as an intervention to improve prehospital patient safety in children | 001 | 1 | NIH | 2/14/2024 | -$147,946 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R03HL171172 | Developing an assessment toolkit and training for teleconsultation as an intervention to improve prehospital patient safety in children | 001 | 1 | NIH | 2/14/2024 | $147,946 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R03HL171172 | Developing an assessment toolkit and training for teleconsultation as an intervention to improve prehospital patient safety in children | 000 | 1 | NIH | 1/22/2024 | $147,946 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK138309 | Effectiveness Trial to Support Adoption of Hybrid Closed Loop Therapy in Underserved Adults with Type 1 Diabetes: Impact of System Functionality and Features on Lived Experience | 001 | 1 | NIH | 4/1/2024 | $0 |
| 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK138309 | Effectiveness Trial to Support Adoption of Hybrid Closed Loop Therapy in Underserved Adults with Type 1 Diabetes: Impact of System Functionality and Features on Lived Experience | 000 | 1 | NIH | 12/29/2023 | $899,996 |
|